Pirlimycin Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is supplied as the crystalline monohydrochloride salt of pirlimycin, a lincosamide antibiotic structurally related to lincomycin and clindamycin. The material is offered in three route-specific grades under the model designations PLM-VET-PIR-HCl-P, PLM-VET-PIR-HCl-M, and PLM-VET-PIR-HCl-G. The P grade is a crystalline powder intended for general formulation development; the M grade is micronized under controlled nitrogen pressure and characterized by laser diffraction according to ISO 13320:2020 for low-dose oral solid and injectable suspension applications; the G grade is densified for granulation and premix blending. Release testing includes identity, HPLC-UV assay, related substances by gradient HPLC, water content by Karl Fischer titration, residual solvents by headspace gas chromatography, residue on ignition, and particle-size distribution. The substance is not a diluted premix and is not intended for human use. It is manufactured under veterinary cGMP controls with verified cleaning procedures to prevent cross-contamination with beta-lactam and sulfonamide APIs.

As a veterinary lincosamide, pirlimycin carries a C-7 chloro substitution on the thioglycoside core and a cis-4-ethylpiperidinyl carbonyl side chain, which distinguish it from lincomycin and clindamycin. These structural features change the API’s lipophilicity, solubility, and antimicrobial spectrum and make the formulated product subject to milk and slaughter withdrawal periods established by the approved finished product, not by the API alone. Ingredient-level substitution with lincomycin hydrochloride or clindamycin hydrochloride in a finished formulation is therefore not permitted without revalidation.

Crystal habit and bulk density may shift batch-to-batch because recrystallization solvent, cooling rate, and drying endpoint affect the powder surface. Receiving tests for bulk and tapped density and particle-size distribution should be used to adjust press speed, fill depth, and blending time. Failure to track these physical properties can produce lot-to-lot variation in tablet weight, capsule fill, and premix homogeneity even when chemical assay remains constant.

Compendial Method Alignment and Release Testing for Multi-Route Supply

Because no harmonized monograph for pirlimycin hydrochloride exists in the United States Pharmacopeia or European Pharmacopoeia, the release specification is built from qualified in-house methods and general chapters. The table below lists the primary test categories and the associated method references.

Injectable-grade release does not use the same residual moisture or microbial limits as the oral or premix grades. The endotoxin and particulate burden of the API are not the sole determinants of finished-product compliance; downstream sterile filtration, terminal heat treatment, and container-closure processing also contribute.

Direct compression of low-dose pirlimycin hydrochloride tablets is controlled by the interaction between particle size, surface charge, and blend humidity. Micronized lincosamide powders with a D90 below approximately 20 µm can improve blend uniformity in a low-dose formulation, but the same size reduction increases triboelectric adhesion to stainless steel tablet tooling when the processing suite remains below 20% RH. This represents a process conflict: low humidity improves flow but worsens electrostatic holding, while higher humidity above approximately 60% RH can produce picking and sticking on rotary tablet presses. Published moisture sorption data for pirlimycin hydrochloride are limited; therefore, the practical humidity window should be mapped for each formulation using instrumented compaction and tablet press run data. For capsules, dosator-type encapsulation machines require a flowable, non-agglomerating powder bed; the M grade may require pre-blending with a free-flowing filler such as spray-dried lactose monohydrate or microcrystalline cellulose to achieve acceptable uniformity. Blend uniformity is verified according to USP <905> with stratified sampling after discharge from tumble or bin blenders. Wet granulation may be preferred when segregation of the micronized API occurs in direct compression; high-shear granulation demands torque and product-temperature endpoints to avoid overwetting, and fluid-bed drying is typically stopped when loss on drying reaches the range defined by subsequent tablet hardness and disintegration testing. Magnesium stearate lubrication should be kept at the minimum level that prevents ejection force excursions, because excessive hydrophobic film formation can delay dissolution of tablets and capsules.

For dry granulation by roller compaction, the ribbon solid fraction and screen milling gap must be tuned to hard, brittle ribbons; if the API is plastically deformable, repeated compaction can reduce porosity and dissolution. Published data specific to pirlimycin hydrochloride in roller-compacted formulations are limited, so ribbon density and granule porosity should be measured during development rather than transferred from lincomycin formulations.

Why Does Injectable Formulation Require a Separate Endotoxin and Particulate Control Strategy?

The API is not inherently sterile. Injectable and intramammary formulations manufactured from pirlimycin hydrochloride powder require either terminal sterilization of the finished solution or aseptic processing through a sterilizing-grade filter. When terminal sterilization is not feasible, aseptic filtration through a 0.22 µm membrane is used; the API particle size distribution and any insoluble excipients determine whether a prefilter is placed upstream to protect the sterilizing filter. Endotoxin control begins with the API because depyrogenation of the bulk powder is difficult after milling and blending.

Buffer selection and pH are critical because pirlimycin hydrochloride contains an ionizable amino group and a thioether. Forced degradation studies under ICH Q1A(R2) conditions are used to bracket the formulation pH and storage temperature. The pH of maximum stability should be confirmed experimentally; pirlimycin-specific kinetic data are limited, and class-level assumptions from clindamycin or lincomycin are not sufficient. Injectable solutions must meet USP <788> particulate matter limits, and for multi-dose vials, antimicrobial effectiveness testing under USP <51> may apply depending on the regulatory filing.

For intramammary infusion, the formulation may require syringability, preservative compatibility, and residence time in the mammary gland. The API grade alone does not confer these properties; they are determined by the formulation base, viscosity, and emulsification or solution state.

For oral powders and premix blends, pirlimycin hydrochloride is typically first passed through a screen and pre-blended with a carrier such as lactose monohydrate, dextrose, or a dust-free vegetable fiber. The primary segregation mechanisms in ribbon and V-blenders are percolation and air entrainment; these are controlled by matching the particle size distribution of the API to the carrier and by avoiding excessive mixer speed. If the P grade is charged into a stationary ribbon blender, an intensifier bar may be required to disperse agglomerates without heat build-up. Blend uniformity is evaluated with stratified sampling, and the resulting premix is tested for moisture content, potency, and bulk density. The G grade is intended to reduce dusting and segregation in this operation, but the densification step may increase disintegration or dissolution time in tablets if it is regranulated and compressed. Oral solutions require clarity after reconstitution; pirlimycin hydrochloride solubility is pH dependent, and hard water can affect the final solution appearance and stability.

Compatibility studies are required before blending pirlimycin hydrochloride with alkalizing agents, strong oxidizers, or acidic effervescent components. Dry blends intended for storage in high-humidity zones should be evaluated for moisture uptake and hydrolysis. Pirlimycin-specific sorption isotherms are not available in public literature for all formulation matrices.

When Pirlimycin Hydrochloride Replaces Lincomycin in Approved Veterinary Formulations

Pirlimycin differs structurally from lincomycin by the presence of a C-7 chloro substituent on the thioglycoside core and by the replacement of the 4-propylproline-derived amide side chain with a cis-4-ethylpiperidinyl carbonyl group. Clindamycin also has the C-7 chloro substitution but retains the lincomycin-type side chain. The structural change in pirlimycin alters lipophilicity and the interaction with the 50S ribosomal subunit in Gram-positive organisms. In vitro activity is directed primarily against staphylococci and streptococci associated with bovine mastitis; however, specific minimum inhibitory concentration data must be generated for the target isolates rather than extrapolated from lincomycin.

From a formulation perspective, pirlimycin hydrochloride is not interchangeable with lincomycin hydrochloride or clindamycin hydrochloride. The salts differ in crystal habit, aqueous solubility, and stability in the presence of alkaline buffers and strong oxidizers. A tablet or injectable formulation that passes release with lincomycin cannot be assumed to pass the same tests with pirlimycin without new dissolution, content uniformity, and stability data. Residual depletion and milk withdrawal are specific to the finished pirlimycin product; they are not governed by the API.

Published data for pirlimycin hydrochloride in tablets, capsules, and premix blends are limited compared with its approved intramammary infusion use.